Comparing the current results to its competitors, Proqr Therapeutics N V reported Revenue decrease in the 4 quarter 2025 year on year by -15.86 %, faster than the overall decrease of Proqr Therapeutics N V 's competitors by -4.87 %, recorded in the same quarter.
Proqr Therapeutics N V 's Comment on Competition and Industry Peers
The pharmaceutical industry is characterized by intense competition and rapid technological advancements. Competitors include large pharmaceutical companies, biotechnology firms, specialty pharmaceutical companies, generic drug manufacturers, academic institutions, government agencies, and research organizations. Key factors influencing competition are efficacy, safety, tolerability, delivery methods, reliability, dosing convenience, patient recruitment, pricing, and reimbursement. Many competitors possess greater financial, technical, and human resources, along with more experience in product discovery, development, regulatory approval, and commercialization. Industry consolidation through mergers and acquisitions may concentrate resources among fewer entities. Competitors may achieve regulatory approvals from agencies such as the FDA or EMA more successfully and gain greater market acceptance. They are also developing technologies in RNA editing, gene editing, gene therapy, small molecules, protein replacement, and antibodies, which could impact the competitiveness of the company's therapies.
April 14, 2025
In the ever-evolving landscape of biotechnology, adaptability and foresight are essential for success. ProQR Therapeutics NV (Nasdaq: PRQR), a pioneering company focused on revolutionary RNA therapies supported by its proprietary Axiomer RNA editing technology, has taken a significant step toward amplifying its growth strategy by announcing the appointments of Dennis Hom as Chief Financial Officer (CFO) and Dr. Cristina Lopez Lopez as Chief Medical Officer (CMO). This strategic move comes as the company gears up to transition its Axiomer platform technology and its promising pipeline of RNA editing programs into the clinical stage.The leadership enhancement signals an important milestone for ProQR. As CFO, H...
October 7, 2024
ProQR Therapeutics NV, a pioneering company in the field of RNA therapies, is poised to present vital preclinical data on its innovative Axiomer RNA editing technology platform at the upcoming 20th Annual Meeting of the Oligonucleotide Therapeutics Society, scheduled for October 6-9, 2024, in Montreal, Canada. This announcement highlights ProQR s ongoing commitment to developing transformative therapies aimed at addressing cholestatic diseases, specifically through their AX-0810 program targeting the sodium-taurocholate co-transporting polypeptide (NTCP).The company s leadership has consistently emphasized the potential of the Axiomer platform to enhance the development of RNA-based therapies. ProQR’s focu...
May 8, 2024
ProQR Therapeutics recently unveiled promising preclinical proof of concept data for its innovative Axiomer RNA editing technology platform. The company s flagship pipeline program, AX -0810, which focuses on addressing cholestatic diseases by targeting NTCP, showcased encouraging results. These significant findings were announced at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, held from May 7-11, 2024, in Baltimore, Maryland.The preclinical data presented outlines the successful utilization of ProQR s Axiomer RNA editing technology platform in targeting NTCP for cholestatic diseases. Cholestatic diseases encompass a range of conditions characterized by the impairment of bile flow, r...
January 19, 2024
ProQR Therapeutics NV, a dedicated company focusing on revolutionizing RNA therapies using its proprietary Axiomer RNA editing technology platform, recently presented significant advancements at the 5th International Conference on Base Editing, Prime Editing and Related Enzymes (Deaminet 2024). The presentation showcased novel updates and breakthroughs that have the potential to impact ProQR s standing in the pharmaceutical industry.Key Facts:1. ProQR Therapeutics NV presented at the 5th International Conference on Base Editing, Prime Editing and Related Enzymes (Deaminet 2024) in San Diego, California.2. The presentation highlighted new platform data related to ProQR s Axiomer RNA editing technology.3. Axio...
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
Morphic Holding Inc's business model revolves around the development and commercialization of novel integrin therapeutics. They utilize a platform that combines structural biology, medicinal chemistry, and computational biology to design and develop small-molecule drugs. By strategically targeting and inhibiting integrin receptors, Morphic aims to address various diseases while offering potential benefits to patients.
Prothena Corporation Public Limited Company Share Performance
-1.96%
This Year
Prothena Corporation Public Limited Company
Profile
Prothena Corporation is a biotechnology company that focuses on developing novel therapies for diseases related to protein misfolding and amyloidosis. Their business model includes leveraging their expertise in antibody and protein engineering to develop and commercialize drug candidates, collaborating with pharmaceutical partners to advance their therapeutic programs, and continuously conducting research and development to expand their pipeline of potential treatments. Their goal is to address unmet medical needs and provide innovative solutions for patients suffering from devastating diseases.
PTC Therapeutics Inc's business model revolves around the research, development, and commercialization of innovative treatments for rare and genetic diseases.
Sources:
Proqr Therapeutics N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Proqr Therapeutics N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
